Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 371.5 INR -1.23% Market Closed
Market Cap: 245.6B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Natco Pharma Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Natco Pharma Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Natco Pharma Ltd
NSE:NATCOPHARM
Accounts Payable
â‚ą3.1B
CAGR 3-Years
27%
CAGR 5-Years
16%
CAGR 10-Years
12%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Accounts Payable
â‚ą30.2B
CAGR 3-Years
9%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Accounts Payable
â‚ą26.8B
CAGR 3-Years
-1%
CAGR 5-Years
5%
CAGR 10-Years
8%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Accounts Payable
â‚ą57.3B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
13%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Accounts Payable
â‚ą21.9B
CAGR 3-Years
7%
CAGR 5-Years
2%
CAGR 10-Years
2%
M
Mankind Pharma Ltd
NSE:MANKIND
Accounts Payable
â‚ą11B
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Natco Pharma Ltd
Glance View

Market Cap
245.6B INR
Industry
Pharmaceuticals

Nestled in the bustling business corridors of Hyderabad, India, Natco Pharma Ltd. has cultivated a strong presence in the pharmaceutical industry over the decades. Founded in 1981, the company initially ventured into the local market, gradually establishing itself as a critical player through specialization in complex chemistry and niche therapeutic sectors. The company's primary focus is on the development and manufacturing of generic drugs, specifically in the oncology and neurology segments. In these high-stakes areas, Natco leverages its robust research and development capabilities to produce affordable alternatives to expensive branded medications, thereby ensuring access to critical treatments for broader populations. Natco Pharma's business acumen extends beyond merely producing generics. It is adept at capitalizing on patent expirations, quickly launching generics and biosimilars in both domestic and international markets. The company has strategically focused operations in markets such as the United States and Europe, where it partners with local distributors to reach end-users. Through a combination of manufacturing efficiencies and strategic partnerships, Natco is able to maintain competitive pricing, thus enhancing its market penetration and revenue generation. Its integrated business model, combining in-house R&D, manufacturing, and distribution, ensures that Natco remains a formidable player, bridging the gap between complex pharmaceuticals and cost-effective healthcare solutions.

NATCOPHARM Intrinsic Value
721.24 INR
Overvaluation 47%
Intrinsic Value
Price

See Also

What is Natco Pharma Ltd's Accounts Payable?
Accounts Payable
3.1B INR

Based on the financial report for Sep 30, 2024, Natco Pharma Ltd's Accounts Payable amounts to 3.1B INR.

What is Natco Pharma Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
12%

Over the last year, the Accounts Payable growth was -14%. The average annual Accounts Payable growth rates for Natco Pharma Ltd have been 27% over the past three years , 16% over the past five years , and 12% over the past ten years .

Back to Top